基于isatuximab的多发性骨髓瘤治疗 - Suppr | 超能文献

Isatuximab-Based Therapy for Multiple Myeloma.

作者信息

Sampath Venkata Sreekanth

机构信息

Tan Tock Seng Hospital, Singapore, Singapore

出版信息

N Engl J Med. 2025 Jan 30;392(5):518-519. doi: 10.1056/NEJMc2414957.

DOI:10.1056/NEJMc2414957

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Isatuximab-Based Therapy for Multiple Myeloma.基于isatuximab的多发性骨髓瘤治疗

N Engl J Med. 2025 Jan 30;392(5):518-519. doi: 10.1056/NEJMc2414957.

2

Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma.关于皮下注射isatuximab治疗复发和/或难治性多发性骨髓瘤患者的简明语言总结。

Future Oncol. 2025 Aug;21(19):2415-2428. doi: 10.1080/14796694.2025.2526281. Epub 2025 Jul 16.

3

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.来那度胺、硼替佐米和地塞米松联合伊沙妥昔单抗用于新诊断、适合移植的多发性骨髓瘤患者的诱导治疗（GMMG-HD7）：一项开放标签、多中心、随机、主动对照、3 期临床试验的第 1 部分。

Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0.

4

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.伊沙佐米、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。

N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3.

5

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。

Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.

6

Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg.卢森堡大公国的病例系列：伊沙妥昔单抗治疗复发/难治性多发性骨髓瘤的真实世界经验。

Hematology. 2023 Dec;28(1):2182098. doi: 10.1080/16078454.2023.2182098.

7

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.isatuximab、卡非佐米和地塞米松用于复发多发性骨髓瘤（IKEMA）：一项多中心、开放标签、随机3期试验

Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4.

8

Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions.isatuximab治疗多发性骨髓瘤：当前临床进展与未来方向

Expert Opin Investig Drugs. 2025 Jul-Aug;34(7-8):571-589. doi: 10.1080/13543784.2025.2532446. Epub 2025 Jul 23.

9

Isatuximab for the treatment of relapsed/refractory multiple myeloma.依沙佐米单抗治疗复发/难治性多发性骨髓瘤。

Expert Opin Biol Ther. 2020 Dec;20(12):1395-1404. doi: 10.1080/14712598.2021.1841747.

10

Radiolabeling and cytotoxicity of monoclonal antibody Isatuximab functionalized silver nanoparticles on the growth of multiple myeloma.单克隆抗体 Isatuximab 功能化银纳米粒子的放射性标记和细胞毒性对多发性骨髓瘤生长的影响。

Int J Pharm. 2022 Aug 25;624:122019. doi: 10.1016/j.ijpharm.2022.122019. Epub 2022 Jul 14.

引用本文的文献

1

A rare dermatological manifestation of follicular spicules in a patient with multiple myeloma and end-stage renal disease on hemodialysis: A case report.一名患有多发性骨髓瘤和终末期肾病且正在接受血液透析的患者出现罕见的毛囊性棘状丘疹皮肤表现：病例报告。

Exp Ther Med. 2025 Jul 23;30(3):180. doi: 10.3892/etm.2025.12930. eCollection 2025 Sep.